References
- Barter ZE, Bayliss MK, Beaune PH, et al. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33–45
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
- Evans G, ed. (2004). A handbook of bioanalysis and drug metabolism. 1st edition. Boca Raton, FL: CRC Press LLC, 318–20
- Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. (2004). Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199:354–63
- Harbourt DE, Fallon JK, Ito S, et al. (2012). Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography–tandem mass spectrometry. Anal Chem 84:98–105
- Mendonza A, Hanna I, Meyers D, et al. (2016). Assessment of pharmacokinetic drug–drug interaction between pradigastat and atazanavir or probenecid. J Clin Pharmacol 56:355–64
- Meyers CD, Amer A, Majumdar T, Chen J. (2015b). Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects. J Clin Pharmacol 55:1031–41
- Meyers CD, Serrano-Wu M, Amer A, et al. (2013). The DGAT1 inhibitor pradigastat decreases chylomicron secretion and prevents postprandial triglyceride elevation in humans. J Clin Lipidol 7:285
- Meyers CD, Tremblay K, Amer A, et al. (2015a). Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis 14:8
- Obach R, Baxter J, Liston T, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
- Pang KS, Rowland M. (1977). Hepatic clearance of drugs. I. Theoretical considerations of a ‘well-stirred’ model and a ‘parallel tube’ model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625–53
- Sawamura R, Okudaira N, Watanabe K, et al. (2010). Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos 38:1857–64
- Shipkova M, Armstrong VW, Oellerich M, Wieland E. (2003). Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1–16
- Yan J-H, Meyers D, Lee Z, et al. (2014). Pharmacokinetic and pharmacodynamic drug–drug interaction assessment between pradigastat and digoxin or warfarin. J Clin Pharmacol 54:800–8